Preclinical Programs
Given Xenon’s expertise in drug discovery, our efforts are concentrated on the identification of targets where we believe novel modulators could represent significant therapeutic advances.
We intend to leverage our deep ion channel expertise to develop promising drug candidates that target sodium and potassium channels, with a near-term focus on internal development candidates targeting Kv7, Nav1.1 and Nav1.7.
Our goal is to advance multiple candidates into IND-enabling studies in 2024 and 2025.
